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Tie2 as a novel key factor of
microangiopathy in systemic sclerosis
Falk Moritz1,2, Janine Schniering1, Jörg H. W. Distler3, Renate E. Gay1, Steffen Gay1, Oliver Distler1
and Britta Maurer1*
Abstract
Background: The angiopoietin(Ang)/Tie2 system is a key regulator of vascular biology. The expression of
membrane bound (mb) Tie2 and Ang-1 ensures vessel stability, whereas Ang-2, inducible by vascular endothelial
growth factor (VEGF), hypoxia, and inflammation, acts as an antagonist. Tie2 signalling is also attenuated by soluble
Tie2 (sTie2), the extracellular domain of the receptor, which is shed upon stimulation with VEGF. Herein, we
investigate the role of Ang/Tie2 in the peripheral vasculopathy in systemic sclerosis (SSc) including animal models.
Methods: The expression of Ang-1/-2 and Tie2 in skin/serum of SSc patients was compared with healthy controls
by immunohistochemistry (IHC)/ELISA. Expression of Ang/Tie2 was analysed in different animal models: VEGF
transgenic (tg) mice, hypoxia model, bleomycin-induced skin fibrosis, and tight skin 1 (TSK1) mice.
Results: In SSc, dermal microvessels abundantly expressed Ang-2, but not Ang-1 compared with healthy controls.
The percentage of mbTie2+ microvessels was profoundly decreased whereas the levels of sTie2 were increased
already in early disease. Both in skin and sera of SSc patients, the Ang1/2 ratio was reduced, being lowest in
patients with digital ulcers indicating vessel destabilizing conditions. We next studied potential influencing factors
in animal models. The VEGF tg mouse model, the hypoxia, and the inflammation-dependent bleomycin model all
showed a similar dysregulation of Ang/Tie2 as in SSc, which did not apply for the non-inflammatory TSK1 model.
Conclusion: Peripheral microvasculopathy in SSc results from a complex dysregulation of angiogenic signalling
networks including the VEGF and the Ang/Tie2 system. The profoundly disturbed Ang-/Tie-2 balance might
represent an important target for vascular therapeutic approaches in SSc.
Keywords: Microvasculopathy, Systemic sclerosis, Angiopoietins, Tie2
Background
Microvascular injury due to dysregulation of angiogenic
factors such as vascular endothelial growth factor
(VEGF) and hypoxia [1–4] is a very early pathogenic
event in systemic sclerosis (SSc) [5]. The Angiopoieti-
n(Ang)/Tie2 system is a key regulator of angiogenesis. The
binding of Ang-1, produced by vascular smooth muscle
cells and other perivascular cells, to the membrane-bound
(mb) Tie2 receptor on endothelial cells (EC) is crucial for
vessel stability. Tie2 activation promotes vessel assembly
and maturation by mediating survival signals for EC and
regulating the recruitment of pericytes [6]. Ang-2, inducible
in EC by VEGF, hypoxia, and inflammation [6–8], antago-
nizes the Ang-1/Tie2 pathway by competing with Ang-1.
Both ligands bind to Tie2 with similar affinity. Under
physiologic conditions, the levels of Ang-1 exceed those of
Ang-2, thereby ensuring the quiescent state of the vascula-
ture. Increased levels of Ang-2 are associated with vascular
remodelling [9]. Furthermore, the effects of Ang-2 are
VEGF-dependent. In the absence of VEGF, Ang-2 has
vessel destabilizing effects and induces regression of
microvessels [10, 11]. In the presence of VEGF, Ang-2 in-
duces angiogenesis with endothelial cell proliferation, migra-
tion and disruption of the vascular basement membrane
due to the increased expression of matrix metalloproteinases
[12]. Thus, the Ang-1/-2 ratio determines the functional
status of the local vasculature. In contrast to mbTie2, little* Correspondence: britta.maurer@usz.ch1Department of Rheumatology, University Hospital Zurich, Gloriastrasse 25,
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is known about soluble Tie2 (sTie2), the extracellular do-
main of the Tie2 receptor, which is released by proteo-
lytic cleavage by matrix metalloproteases upon
stimulation with VEGF in a process also referred to as
shedding [13, 14]. sTie2 is detectable in healthy individ-
uals, and increased serum concentrations were mea-
sured in cardiovascular diseases, diabetic retinopathy
[15], and SSc [16, 17].
Previous studies supported an equal affinity of Ang-1
and Ang-2 for the Tie2 receptor [10, 11, 13]. Interest-
ingly, a recent study reported a higher affinity of Ang-1
to sTie2, which indicates that sTie2 might shift the
Ang-1/Ang-2 ratio in favour of Ang-2 thereby inducing
destabilization and regression of microvessels [18].
Other studies suggest competitive binding to mbTie2
thereby blocking access for Ang-1/-2 with inhibition of
downstream signalling [6]. The scheme in Fig. 1
summarizes the current concept of the role of Ang/Tie2
in vascular remodelling.
In the present study, we assessed alterations of the
Ang/Tie2 system in SSc-associated dermal microvascu-
lopathy and in different animal models of SSc.
Methods
Patients
Serum samples were obtained from patients with
limited cutaneous (lc) SSc (n = 21) and diffuse cutane-
ous (dc) SSc patients (n = 13) fulfilling the LeRoy cri-
teria [19], patients with early SSc not yet fulfilling the
LeRoy criteria (= pre-SSc) (n = 12), and from age- and
sex-matched healthy donors (n = 40). The patients were
56.2 ± 11.6 years old, the majority was female (75%).
The average disease duration was 6.3 ± 4.64 years. All
patients had Raynaud’s phenomenon, 68% had a history
of digital ulcers, 37% had current digital ulcers, and
93% had teleangiectasias. The majority of patients were
ANA positive (88.3%). A total of 39% were positive for
anti-Scl-70, 44% for anti-centromere, and 2% for anti-
Fig. 1 The role of Angiopoietins and Tie2 in vascular biology (adapted from [6–8, 11, 13, 14]). a In quiescent state, Ang-1, produced by pericytes,
acts in a paracrine manner on the membrane-bound (mb) Tie2 receptor on endothelial cells (EC). The effects of Ang-1/Tie2 signalling ensure
vessel stabilization. Ang-2, produced by EC, is stored in Weibel-Palade bodies. b In hypoxia and inflammation, Ang-2 is released from the Weibel-
Palade bodies and acts in an autocrine manner on EC. Due to competitive binding to mbTie2, Ang-2 antagonizes Ang-1 signalling. In the absence
of VEGF, the inhibition of Tie2 signalling leads to vessel destabilization and regression due to apoptosis of EC, loss of pericyte coverage and disrupture
of the basement membrane. In the presence of VEGF, Ang-2 exerts pro-angiogenic effects with proliferation and migration of EC and sprouting of
new branches. Additionally, VEGF causes shedding of Tie2. sTie acts as competitive ligand for Ang-1/-2 thereby blocking downstream signalling with
anti-angiogenic effects. Ang Angiopoietin, VEGF vascular endothelial growth factor
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RNA-polymerase III. The majority of patients had an
active pattern in the nailfold capillaroscopy, whereas
33% showed a late, and 17% an early, pattern [20]. Skin
biopsies were obtained by punch biopsies from involved
skin at the forearms from 24 of the above mentioned
SSc patients (13 lcSSc, 11 dcSSc) and from 19 of the
above mentioned healthy controls. All participants had
signed a consent form approved by the local institu-
tional review boards. The study had been approved by
the cantonal ethics committee Zurich.
Animals
VEGF tg mice
To investigate the effect of VEGF on Ang/Tie2, VEGF
homo- (+/+) (n = 8) and heterozygous (+/−) (n = 9)
transgenic (tg) mice and wildtype (wt) littermates (n =
6/9) were analysed. VEGF tg mice have been described
previously [21]. Briefly, in VEGF tg mice, the murine
VEGF164 gene which is the murine equivalent to
VEGF-A165, was cloned into a human keratin 14 pro-
moter expression cassette which had previously been
shown to selectively target transgene expression to
basal keratinocytes of the skin [21]. VEGF tg mice were
on the FVB background.
Hypoxia model
Four- to six-week-old female C57BL/6 mice (n = 3) were
exposed to systemic normobaric hypoxia by substitution
of oxygen with nitrogen in a closed Perspex chamber
using a Digamix 2 M 302/a-F pump (H. Woesthoff
GmbH, Bochum, Germany) at a flow rate of 37 l/min.
When mice were placed into the chamber, O2 fractions
were decreased gradually from 21 to 6% within 1 h and
mice were kept in the hypoxic chamber for additional 24
to 48 h. In parallel, nine littermates were kept under
normoxic conditions. The experimental set-up was described
previously [4].
Bleomycin-induced skin fibrosis in mice
The bleomycin model is a frequently used model of
chemically induced dermal fibrosis. The bleomycin-
induced skin fibrosis in mice is considered as an animal
model that mimics early, pro-inflammatory stages of
skin fibrosis in SSc. Skin fibrosis was induced in 6- to
8-week-old C57/BL6 mice (n = 4) by local injections of
bleomycin for 21 days as previously described [22].
Briefly, 100 μl of bleomycin dissolved in 0.9% sodium
chloride (NaCl) at a concentration of 0.5 mg/ml was
administered every other day by subcutaneous injec-
tions in defined areas of the upper back. Subcutaneous
injections of 100 μl 0.9% NaCl were used in a second
group (n = 4) as controls.
TSK1 mice
Compared to the bleomycin model, tight skin 1 (TSK1)
mice [23] are considered as a late-stage, non-inflammatory
model of skin fibrosis in SSc. Due to a dominant mutation
of the fibrillin 1 gene, TSK1 mice develop an increased der-
mal and especially hypodermal thickness. TSK1 mice were
interbred with pa/pa mice in which a recessive mutation
(pa) induces a light grey colour of the fur and pink eyes. Be-
cause the fibrillin 1 gene is genetically linked to the pa gene,
mice can be screened for the tsk1 mutation based on the
colour of eyes and fur. All mice with black fur and eyes
carry the dominant tsk1 mutation and are heterozygous for
the pa mutation. In contrast, mice with grey fur and pink
eyes do not carry the tsk1 mutation, but are homozygous
for the mutated pa gene. Apart from changing the skin
colour, the pa mutation does not alter skin physiology and
has no impact on skin fibrosis [23]. In the current experi-
ments, four TSK1 and four pa/pa mice were analysed.
The animal protocols were approved by the cantonal
veterinary office Zurich.
Immunohistochemistry
Murine and human skin samples were fixed in 4%
formalin and embedded into paraffin as described
previously [24]. For immunohistochemistry, 5 μm thick
sections of human and murine skin were used. Immuno-
histochemical double stainings were performed in se-
quential order. On the first day, after pre-treatment with
citrate buffer, the slides were incubated with primary
rabbit polyclonal von Willebrand Factor (vWF) antibody
(Abcam, Cambridge, UK) at room temperature for 1 h,
followed by incubation with biotin-labelled secondary
goat anti-rabbit antibody (Jackson ImmunoResearch,
Soham, UK). Staining was visualized with ABC phos-
phatase kit (Vector Laboratories, Burlingame, CA,
USA) and developed using Vector blue. After additional
heat-mediated treatment with citrate buffer, sections
were incubated with primary rabbit polyclonal Ang-1
or Ang-2 antibodies (Abcam) overnight at 4 °C, followed
by incubation with biotin-labelled secondary goat anti-
rabbit antibodies (Jackson ImmunoResearch). Stainings
were visualized using an ABC peroxidase kit and devel-
oped using DAB (Vector Laboratories). The sequential
staining with Tie2 was performed similarly with the
exception that no additional heat-mediated removal was
required on the second day since the primary Tie2 anti-
body was mouse monoclonal (Abcam). Isotype-matched
IgGs were used as negative controls.
Analysis of skin sections
The analyses of all immunohistochemical stainings
were performed by two independent examiners who
were blinded with regard to the different groups. All
slides were analysed twice by each examiner. In case of
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a variation of the results >10%, the respective slides were
re-assessed to reach consensus. Pictures were taken with a
slide scanner (Zeiss Axio Scan.Z1), using Zen lite software
(blue edition 2.3) (Carl Zeiss Microscopy GmbH, Jena,
Germany).
For the semi-quantitative analysis of microvessel
density, pictures of five randomly chosen high power
fields (HPF)/slide were taken. Then, vWF+ blood vessels
(dermal microvessels) were counted. Either the ratio or
the percentage of Ang-1+, Ang-2+, or Tie2+ blood ves-
sels was determined by assessing their numbers referred
to the total number of vWF+ microvessels/HPF using
the respective double stainings. Blood vessel density was
assessed in the dermis without the epidermal and the
subdermal layers, except for the TSK1 mice in which the
hypodermis was analysed. The number/percentage of
microvessels was then calculated for each group using
GraphPad Prism software (GraphPad Software Inc., San
Diego, CA, USA).
ELISA
Serum concentrations of Ang-1/-2 and sTie2 were mea-
sured using the colorimetric sandwich ELISA technique
(Quantikine; R&D Systems, Abingdon, UK).
Real-time PCR
Biopsy specimens (0.5 cm2) were homogenized with Tis-
sueLyser (Qiagen, Basel, Switzerland). Total RNA was iso-
lated using the RNeasy Mini Kit (Qiagen, Hombrechtikon,
Switzerland) and reverse transcribed into complementary
DNA (cDNA) with random hexamers [25]. Expression
of murine Ang-1, Ang-2, TEK (= Tie), and 18S rNA
was measured using TaqMan Gene Expression Assays
(Applied Biosystems, Basel, Switzerland). qPCR was
performed using a 7500 Real-Time PCR System (Applied
Biosystems). All qPCR experiments were performed in
duplicate.
Cell culture, reagents, stimulation assay, and analysis
Human dermal microvascular endothelial cells (HMVEC-
d adult, Cambrex, Rockland, ME, USA) were cultured in
six-well plates in endothelial cell medium (EGM-2 MV,
Lonza, Basel, Switzerland), and passages 3–8 were used
for analysis. After 24 h of serum reduction, HMVECs were
stimulated for 12, 24, and 48 h with recombinant VEGF-
A165 (R&D Systems) at concentrations of 2.5, 5, and
10 ng/ml. Controls were exposed to equivalent dosages of
the carrier protein BSA [26]. sTie was measured by ELISA
as described above in cell culture supernatants. The
percentage of Tie2+ cells was evaluated using flow cy-
tometry analysis (FACS) according to the instructions
of the manufacturer. Briefly, HMVECs were washed
with PBS, detached with trypsin/0.5% EDTA and centri-
fuged at 200 × g for 5 min. Afterwards cell pellets were
resuspended and incubated for 15 min at room
temperature with the primary Tie2 antibody. Isotype-
matched IgGs were used as negative controls. The ana-
lysis was performed using the FACScan flow cytometer
(Becton Dickinson, Mansfield, MA, USA). Data were
analysed with CellQuest software (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA).
Statistical analysis
For statistical analysis, GraphPad Prism software (version
5.01) was employed (GraphPad Software Inc.). Normal
distribution of data was examined using the Kolmogorov-
Smirnov test. For parametric non-related data, expressed
as mean ± standard error of the mean (SEM), the unpaired
two-tailed t test was used. Nonparametric non-related
data, expressed as median(Q1, Q3) were analysed employing
the Mann-Whitney U test. P values less than 0.05 were
considered statistically significant.
Information on the histology and assessment of skin
fibrosis in the bleomycin model and the measurement of
collagen contents by hydroxyproline assay is provided in
Additional file 1 supplemental methods.
Results
Dysregulation of the Ang/Tie2 system in the dermal
microvasculopathy in SSc
In skin biopsies of SSc patients, the microvascular dens-
ity was generally reduced compared with healthy con-
trols (ratio of vWF+ vessels/HPF 27.3(24,38) vs. 45.5(31,60);
p = 0.001; Fig. 2a, b). Dermal capillaries of SSc patients
expressed Ang-2 more abundantly than healthy controls
(Fig. 2a, b) (ratio of Ang-2+/vWF+ microvessels/HPF
1.7(1.3,2.5) vs. 1.1(0.8,1.3); p = 0.01). Most impressively, the
percentage of mbTie2-positive microvessels was strongly
and consistently decreased in the skin of SSc patients
compared with healthy controls (median(quartile range)
3.8(1,6)% vs. 87(78,99)%; p < 0.001) (Fig. 2a, b). The expres-
sion of Ang-1 did not differ in dermal capillaries of SSc
patients compared with healthy controls (Fig. 2a). In the
analysed sections, no difference in the expression of
Ang-1/-2 or Tie2 could be observed between lcSSc or
dcSSc. Furthermore, to evaluate whether the changes on
tissue level were reflected on systemic level, we add-
itionally measured the serum levels of Ang-1, Ang-2,
and sTie2. To evaluate whether the loss of mbTie2 in
dermal microvessels might be due to shedding [13], we
assessed the serum levels of sTie2, which is the soluble,
cleaved, extracellular domain of the Tie2 receptor.
Indeed, sTie2 levels of SSc patients were higher than
those of healthy controls (mean ± SEM 9.6 ± 1.7 ng/ml)
without differences between the lcSSc or dcSSc subsets
(16.7 ± 7.5, 13.6 ± 1.7 ng/ml; p < 0.01) (Fig. 3a). In
accordance with the shedding hypothesis, treatment of
human dermal microvascular endothelial cells (HMVECs)
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with increasing dosages of VEGF for 12 h reduced the
numbers of Tie2-positive cells by 9.6, 20.2, and 25.1%
whereas in parallel there was an increase of the sTie2 con-
centration in the supernatants by 47 to 57% (Fig. 3b).
Serum Ang-2 levels were increased in both lcSS and dcSSc
patients as compared with healthy controls (1.4 ± 0.2 and
1.5 ± 0.3 vs. 0.3 ± 0.02 ng/ml; p < 0.01) whereas the Ang-1
levels where remarkably lower (18.4 ± 5.7 and 32.9 ± 10.3
vs. 68.4 ± 5.4 ng/ml; p < 0.01) (Fig. 3a). Irrespective of the
cutaneous subtype, in the whole group of SSc patients
with established disease, the serum levels of Ang-1 (23.9 ±
5.3), Ang-2 (1.5 ± 0.2), and sTie2 (17.9 ± 1.1) differed sig-
nificantly from healthy controls (p < 0.001, respectively).
The imbalance towards Ang-2 in patients with lcSSc and
dcSSc resulted in a strongly reduced Ang-1/-2 ratio as
compared with healthy controls (13:1 and 23:1 vs. 221:1,
respectively; p < 0.05. Interestingly, SSc patients with
digital ulcers had a significantly lower Ang-1/Ang-2 ra-
tio as compared with those without (2.4(2,3) vs. 7.2(7,9);
p < 0.02). In contrast, patients with teleangiectasias had
a significantly higher Ang-1/Ang-2 ratio (1.9 ± 0.4 vs.
1.3 ± 0.08; p < 0.05) than those without. Most import-
antly, in patients with pre-SSc, serum levels of Ang-1/-2
already differed significantly from healthy controls (35.5 ±
8.8 vs. 68.4 ± 5.4 ng/ml and 0.9 ± 0.2 vs. 0.3 ± 0.02 ng/ml;
p < 0.02) (Fig. 3a). Serum levels of sTie2 were as high as in
patients with established disease and thus remarkably ele-
vated compared with healthy controls (14.4 ± 1.9 vs. 9.6 ±
1.8 ng/ml; p = 0.01) (Fig. 3a). Of note, in line with previous
results [2, 3], pre-SSc patients also had significantly ele-
vated serum VEGF levels compared with healthy controls
(481(120,559) vs. 101(10,169); p = 0.01), which were as high as
Fig. 2 Expression of Ang/Tie2 in dermal microvessels of SSc patients and controls. a As assessed by double (+/+) staining of skin biopsies, Ang-2
(red staining) was more abundantly expressed in dermal microvessels (vWF+; blue staining) of SSc patients compared with healthy controls,
whereas Ang-1 (red staining) did not differ. The expression of the membrane-bound Tie2 receptor (red staining) was remarkably reduced in
dermal microvessels (vWF+; blue staining) of SSc patients compared with healthy controls. Vessels are indicated by arrows. b shows the respective
semi-quantitative analyses of dermal Ang-2 and mbTie2 expression as well as the reduced microvascular density of SSc patients compared with
healthy controls. Pictures are representative examples of 24 SSc patients and 19 healthy controls. Ang Angiopoietin, SSc systemic sclerosis, vWF
von Willebrand factor
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in patients with established disease (lcSSc 412(250,609) and
dcSSc 634(404,941) pg/ml).
In summary, we observed a severe disturbance in the
expression of Ang-1 and Ang-2 as well as of Tie2 in the
skin and sera of patients SSc.
Potential influences on the Ang/Tie2 expression in vivo
To assess which pathogenic factors in SSc might affect
the expression of Ang/Tie2, we evaluated pathophysio-
logically different animal models of SSc. First, we studied
the Ang/Tie2 system in a vascular model of SSc, using
the VEGF tg mice since VEGF plays a key role in SSc-
associated microvasculopathy and has been suggested to
strongly influence the effects of Ang/Tie2 on vascular
remodelling [6, 13] (Fig. 1). As previously shown, VEGF
tg mice develop a proliferative vasculopathy with tortu-
ous and dilated capillaries with increased vessel wall
thickness reminiscent of both the capillary changes ob-
served in SSc [1] and in Ang-2-overexpressing mice
[11]. In VEGF+/+ tg mice as compared with VEGF+/- tg
mice, chronically high levels of VEGF dampen the pro-
angiogenic effects of VEGF [1], which is similarly ob-
served in SSc patients with a chronically elevated VEGF
levels and insufficient angiogenesis [2, 3].
In VEGF-+/- and VEGF+/+ tg mice, a higher pro-
portion of dermal microvessels (vWF+) expressed
Ang-2 compared with wt mice (% of Ang-2+/vWF+
microvessels/HPF 100(78,100) and 100(100,100) vs.
36.7(0,57); p = 0.004, p = 0.0003) (Fig. 4a), whereas Ang-
1 was reduced (% of Ang-1+/vWF+ microvessels/HPF
0(0,50) and 20(0,50) vs. 75(66.7,75); p = 0.04, p = 0.05)
(Fig. 4b). Of note, expression of mbTie2 was remark-
ably reduced in the dermal capillaries (vWF+) of both
VEGF+/- and VEGF+/+ tg mice as compared with con-
trols (% of Tie2+/vWF+ microvessels/HPF 50(25,100) and
16.7(0,50) vs. 100(88.3,100); p = 0.03, p = 0.0006) (Fig. 4c).
These observations are in line with previous data showing
that VEGF tips the balance towards Ang-2 and decreases
the local expression of mbTie2 [27]. Furthermore, the de-
creased Ang-1/-2 ratio with a strong concomitant loss of
Fig. 3 Serum levels of Ang/Tie2 in SSc patients and controls and effects of VEGF on human dermal microvascular endothelial cells. a As assessed
by ELISA, serum levels of Ang-2 were significantly increased in patients with pre-SSc as well as in established disease irrespective of the disease
subset (lc = limited cutaneous vs. dc = diffuse cutaneous) compared with healthy controls. In contrast, the Ang-1 levels were remarkably decreased
in all different SSc subsets compared with healthy controls. Of note, all SSc patients irrespective of cutaneous subtype or disease stage showed
elevated serum concentrations of sTie2 compared with healthy controls. b. Treatment of dermal HMVECs with recombined human VEGF led
to a dose-dependent reduction of Tie2+ cells with concomitant increase of sTie2 in the supernatants thereby supporting the shedding
hypothesis. Ang Angiopoietin, SSc systemic sclerosis, sTie2 soluble Tie2, VEGF vascular endothelial growth factor
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mbTie2 in chronic VEGF exposure in vivo mirrored the
observed changes in SSc (Fig. 2).
Tissue hypoxia is a known phenomenon in SSc [2, 4].
To evaluate whether hypoxia might contribute to the
dysbalance of the Ang/Tie2 system in SSc, we analysed
the tissue expression in hypoxic compared to normoxic
mice. Whereas the expression of Ang-1 mRNA did not
change, Ang-2 and Tie2 mRNA transcripts increased
on the tissue level in hypoxia (2.4 ± 0.4-fold; p = 0.027
and 2.6 ± 0.8-fold; p = 0.042) compared to normoxia
(Additional file 2). Our data are in accordance with
previous studies showing that hypoxia increases the
expression of Ang-2 [6]. Since Ang-2 blocks Tie2 sig-
nalling, this ultimately leads to vessel destabilization
and regression [6].
Since inflammation is another characteristic patho-
genic feature in early stages of SSc, we next assessed
the expression levels of Ang/Tie2 in the model of
bleomycin-induced skin fibrosis [28] since it mimics
early, inflammatory stages of SSc [29]. Treatment with
bleomycin resulted in significant skin fibrosis as measured
by increase in dermal thickness (mean ± SEM 1.5 ± 0.05-
fold) and hydroxyproline contents (1.6 ± 0.1-fold; p < 0.05
each) (Additional file 3). Interestingly, there was a trend
towards a higher percentage of Ang-2+ dermal microves-
sels (vWF+) in bleomycin-challenged mice vs. saline-
treated controls (% of Ang-2+/vWF+ microvessels/HPF
95.8 ± 2.7 vs. 65 ± 15; p = 0.08) (Fig. 5a). No differences
were observed for the expression of Ang-1 in controls and
bleomycin-treated mice (% of Ang-1+/vWF+ microves-
sels/HPF 66.7(66.7,75) vs. 100(66.7,100); p = 0.3) (Fig. 5b). The
expression of mbTie2 in dermal capillaries (vWF+) was
lower in bleomycin-treated mice vs. saline-treated controls
(% of Tie2+/vWF+ microvessels/HPF 50(33,75) vs.
100(94,100); p = 0.002) (Fig. 5c). These observations are in
line with recent data giving evidence of that in inflamma-
tory conditions, the expression of Ang-2 is increased
whereas the expression of mbTie2 is decreased [7].
Finally, we investigated the dermal expression of Ang/
Tie2 in an inflammation-independent, late-stage model
Fig. 4 Expression of Ang/Tie2 in dermal microvessels of VEGF tg mice. Overall, the changes in VEGF tg mice reflected the changes observed in
human SSc. a In VEGF +/- tg mice, the percentage of Ang-2 positive (brown staining) dermal microvessels (vWF positive, blue staining) was
significantly increased compared with wt mice (vessels indicated by arrows). The same could be observed in VEGF +/+ tg mice. b In contrast,
VEGF +/- and VEGF+/+ tg mice showed a lower percentage of Ang-1 (brown staining) dermal microvessels (vWF positive; blue staining) compared
with controls. Double-stained vessels are indicated by arrows with an open arrowhead whereas vessels being only positive for vWF are indicated
by arrows with a closed arrowhead. c The expression of membrane-bound Tie2 (mbTie) (brown staining) was remarkably reduced in the microvessels
(vWF positive; blue staining) of VEGF +/- and +/+ tg mice compared with wt mice Vessels are indicated by arrows. Pictures are representative examples
of +/– (+/−) (n = 9) and +/+ (+/+) (n = 8) VEGF tg mice and respective controls (n = 6/9). +/- heterozygous, +/+ homozygous, Ang Angiopoietin, vWF
von Willebrand factor, wt wildtype
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of SSc, the TSK1 model [30]. In TSK1 mice, the expres-
sion of Ang-2 in capillaries (vWF+) was not changed
compared with pa/pa controls (100(50,100) vs. 100(88,100);
p = 0.9) (Fig. 6a). No statistically significant difference
was observed in TSK1 mice vs. pa/pa controls neither
for Ang-1 (% of Ang-1+/vWF+ microvessels/HPF 0(0,25)
vs.25(0,75); p = 0.2) nor for mbTie2 (% of Tie2+/vWF+
microvessels/HPF 58.4(13,67) vs. 100(0,100), p = 0.2) (Fig. 6b,
c) although there was a tendency to a reduction of Tie2
+ microvessels in TSK1 mice.
Discussion
In SSc, peripheral microvasculopathy is a key pathogenic
event. Our results suggest that a dysbalance of Ang/Tie2
might contribute to the vascular changes. An excess of
Ang-2 over Ang-1 – as herein observed on tissue and
serum level – is known to induce vascular remodelling
by blocking Tie2 signalling on EC [6, 10, 11] (Fig. 1).
Interestingly, SSc patients with digital ulcers showed a
significantly lower Ang-1/-2 ratio as compared with
those without, which further underlines the potential
clinical relevance of the observed alterations although
the low number of patients and the heterogeneity of
the disease warrant some caution in the interpretation
of these results. Depending on the absence/presence of
VEGF [6, 13], the destabilization of vessels might then
lead to regression or (disorganized) sprouting (Fig. 1),
both well-described events in SSc microvasculopathy.
Moreover, the substantial loss of mbTie2 on dermal
microvessels in SSc with concomitant increase in sTie2,
which also competes with Ang-1, further impairs Tie2
signalling (Fig. 1). Notably, treatment of dermal HMVECs
with VEGF led to a dose-dependent reduction of
Tie2+ cells with concomitant increase of sTie2 in
Fig. 5 Expression of Ang/Tie2 in dermal microvessels of bleomycin-challenged mice. a, b In bleomycin-treated mice, no significant difference in
the expression of Ang-2 or Ang-1 (brown staining) could be observed in dermal microvessels (vWF positive; blue staining) compared with
saline-treated controls. Vessels are indicated by arrows. c The percentage of mbTie2 positive (brown staining) dermal microvessels (vWF
positive; blue staining) was significantly higher in bleomycin- vs. saline-treated mice. Vessels are indicated by arrows. Pictures are representative
examples of four bleomycin-treated and four saline-treated controls. Ang Angiopoietin, HPF high power field, vWF von Willebrand factor,
wt wildtype
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the supernatants thereby supporting the shedding hypoth-
esis. Interestingly, a similar dysbalance of Ang-1/-2, sTie2,
and VEGF levels was already observed in pre-SSc patients
as in patients with established disease indicating that the
disturbance of angiogenic signalling networks is an early
pathogenic event.
Our data on the expression of angiopoietins and Tie2
in dermal microvessels of SSc patients extend previous,
partially conflicting results on the systemic levels of
Ang-1/-2 and sTie2 in SSc. Interestingly, all available
studies [16, 31–33] as well as our own data found
increased systemic levels of Ang-2 without differences
regarding lcSSc or dcSSc subtypes [32, 33]. Data on
Ang-1 are more ambiguous. Whereas Michalska et al.
reported a similar reduction of Ang-1 levels and the
Ang-1/Ang-2 ratio in SSc [16], the study by Dunne et al.
showed an increase of Ang-1 in the dcSSc subset, but
not the combined SSc group as compared with healthy
controls [32]. However, apart from discrepancies that
might arise from studying such a heterogeneous disease,
these differences might also be attributed to the use of
plasma [32] instead of serum. Similar to our observations,
the serum levels of sTie2 were found to be elevated by
Noda et al [17] and Dunne et al. [32], however, the latter
study only demonstrating significant differences in the
lcSSc subgroup. The study by Gerlicz et al. showed a trend
towards higher levels of sTie2 in both SSc subsets com-
pared with healthy controls, yet the data were not statisti-
cally significant [33]. But again, all these studies including
our own have only analysed very limited numbers of pa-
tients. Therefore, the observed changes of serum/plasma
angiopoietin and sTie2 levels in SSc and particularly their
correlation with clinical (vascular) features warrant a stan-
dardized and systematic evaluation in a large, multicentre
cohort. Apart from the fact that in most published studies
not all three parameters (Ang-1, Ang-2, sTie2) have been
Fig. 6 Expression of Ang/Tie2 in dermal microvessels of TSK1 mice. a, b, c In the TSK 1 model, no significant changes could be observed with
respect to the expression of Ang-2, Ang-2, Tie2 (brown staining) in microvessels (vWF positive; blue staining) in the hypodermis. Vessels are
indicated by arrows. Pictures are representative examples of four TSK mice and four pa/pa controls. Ang Angiopoietin, HPF high power field, TSK1
tight skin 1, vWF von Willebrand factor
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simultaneously analysed, some of the current discrepan-
cies of the association with clinical vascular features might
arise from differences such as treatment (vasodilating
agents, immunosuppressive drugs), the definitions of
ulcers and nailfold capillaroscopy patterns used, but also
biobank-related issues such as different processing and/or
storage of blood samples and use of different ELISA
assays. Thus, although the current available data support a
dysbalance of the Ang/Tie2 system in SSc, the clinical
implications have yet to be elucidated including the per-
formance of more detailed functional in vitro experiments.
Our in vivo data derived from the different animal
models, which closely mirrored the changes observed in
SSc patients, suggested that VEGF, hypoxia, and inflam-
mation might play a role in the dysbalance of the Ang/
Tie2 system in SSc.
Conclusions
Thus, our data extend the previous concept of periph-
eral microangiopathy in SSc [1–4, 34] giving novel
evidence on tissue level of an even more complex dys-
regulation of angiogenic key players. The dysregulation
of the Ang/Tie-2 system appears to be specific for vas-
cular and inflammatory conditions, as the non-vascular
and inflammation-independent TSK1 model did not
reflect the changes observed in the human disease. This
further underlines that for proof of concept studies the
appropriate choice of an animal model that closely
reflects the situation of the human disease, is of out-
most importance [35]. However, for the development of
targeted treatment strategies those interactions and
their biologic relevance will first have to be carefully
and thoroughly studied in suitable preclinical settings
including detailed functional experiments and specific
animal models.
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